Astellas Pharma Inc. Newsletter
-
How the FDA’s Lax Generic Drug Rules Put Her Life at Risk
19 Dec 2025 11:54 GMT
… a specially trained transplant pharmacist with two decades of … called Astellas, which had discovered and patented the drug. When … pharmacy. Cochrane expected to see steady levels of the drug … since some states bar pharmacists from automatically dispensing a …
-
Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer
18 Dec 2025 06:45 GMT
(RTTNews) - Astellas Pharma Inc. and Pfizer Inc. announced … ), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda …
-
Aviceda Therapeutics to advance eye disease drug despite Phase IIb loss
16 Dec 2025 18:53 GMT
… no statistical difference compared to Astellas Pharma’s Izervay (avacincaptad pegol), … and Drug Administration (FDA) approval in August 2023, Apellis Pharmaceuticals’ Syfovre … Arena.
Other companies investigating drugs for GA include Boehringer Ingelheim …
-
Phase 3 Trial Shows Survival Gains in Muscle-Invasive Bladder Cancer
19 Dec 2025 17:20 GMT
Astellas Pharma and Pfizer have … B15, evaluated the antibody-drug conjugate and immunotherapy combination … cisplatin-ineligible patient populations.
Astellas highlighted the broader implications … head of oncology development at Astellas, said the EV-304 …
-
Prostate Cancer Treatment Market is expected to reach US$ 28.10 billion by 2033 | DataM Intelligence
19 Dec 2025 09:31 GMT
… immunotherapeutics, and advanced hormonal drugs. Meanwhile, North America leads … between oncology drug developers, and rising drug approvals further advance … market include:
Astellas Pharma
AstraZeneca
Bayer AG
Dendreon Pharmaceuticals
Exelixis Inc …
-
Novo files for CagriSema approval; Merck and Pfizer’s trial win
19 Dec 2025 20:18 GMT
… the Danish drugmaker disappointed investors when the drug, a combination … focused on antisense oligonucleotide drugs that boost gene expression … the Pfizer/Astellas antibody-drug conjugate Padcev succeeded … commercialization of any drugs that emerge from …
-
Improving Diagnosis of Aortic Stenosis with Genetics and AI
19 Dec 2025 17:23 GMT
… fees from Roche Diagnostics and Astellas Pharma. Khurshid receives sponsored research support …
-
Padcev-Keytruda notches another Phase III win in bladder cancer
18 Dec 2025 18:47 GMT
A combination of Pfizer and Astellas’ Padcev (enfortumab vedotin) … trial (NCT04700124), the antibody-drug conjugate (ADC) and … the US Food and Drug Administration (FDA) greenlight …
According to GlobalData’s Pharmaceutical Intelligence Center, the best …
-
<![CDATA[Enfortumab Vedotin Combo Improves Survival in Cisplatin-Eligible MIBC]]>
17 Dec 2025 21:27 GMT
… news release from the developer, Astellas Pharma.1
Efficacy findings from the … , head of oncology development at Astellas, concluded. 1
PADCEV™ plus Keytruda … of cisplatin eligibility. News release. Astellas Pharma. December 17, 2025. Accessed December …
-
<![CDATA[Padcev/Keytruda Combo Extends Survival in Muscle-Invasive Bladder Cancer ]]>
17 Dec 2025 19:01 GMT
… in a news release from Astellas Pharma Inc., the trial met its … , head of Oncology Development at Astellas, concluded in the press release … Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17 …
About
© 1995-2025